PL BioScience is a welcome addition to the cell therapy cluster in the south of the Netherlands. To enhance research activities and increase development, PL BioScience will set up a complementary work space at Medace.
Hatim Hemeda, CEO and co-founder: ‘At PL BioScience, we highly value the cooperation with Medace. The innovative and inspiring work environment gives us the opportunity to enhance the development of tomorrow’s cell culture tools. That perfectly matches our mission to promote an animal-free future of cell culture solutions.’
PL BioScience will be making use of Medace’s research and cleanroom facility to develop new products. The company, financially supported by Brightlands Venture Partners, has developed an advanced nutrient solution for the cultivation of cells under lab conditions. This can replace the previous standard among cell culture media, Fetal Bovine Serum (FBS), and helps researchers to switch to animal suffering-free products. The products of PL BioScience are based on Human Platelet Lysate.
With the welcoming of PL BioScience a nice synergy is created with one of Medace’s other clients InoCells. InoCells makes use of the PL BioScience product in the development process of their cell therapy product for the treatment of ovarian insufficiency. A nice win-win is therefore created.